NEUTEC PHARMA COMPLETES RECRUITMENT IN BREAST CANCER STUDY

A A

NeuTec Pharma has reported that patient recruitment in its clinical study in breast cancer patients has been completed ahead of schedule. The Phase Ib, pharmacokinetic, multicenter, open-label study is evaluating the safety and efficacy of Mycograb administered in combination with Docetaxel in metastatic or recurrent breast cancer patients.

The primary objective of the study is to observe the safety and tolerability of Mycograb administered in combination with current gold standard therapy. The secondary objective of the study is to monitor the response rate of the target tumors and overall survival and progression-free survival through seven months post-treatment.